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tion occurred among 36% and 50% of P-PGI2 and NP-PGI2 patients, respectively; mean 
(SD) weeks to augmentation were 7 (15) and 3 (8). ConClusions: Use of other PAH 
therapies prior to PGI2 is common, particularly among NP-PGI2. Our findings suggest 
that parenteral PGI2 may be reserved for more severe PAH patients.
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objeCtives: The long-term use of ß-blockers has been shown to improve the out-
comes of patients with heart failure (HF). However, it is still disputed whether this 
is a class effect, and, specifically, whether carvedilol or bisoprolol are superior to 
metoprolol tartrate. The objective of this study is to compare the effectiveness of 
ß-blockers for patients with HF in a clinical practice. Methods: We conducted an 
observational cohort study using the Quebec administrative databases to identify 
patients with HF who were prescribed a ß-blocker after the diagnosis of HF e.g. 
metoprolol tartrate, carvedilol or bisoprolol. We used descriptive statistics to charac-
terize the patients by the type of ß-blocker prescribed at discharge. The unadjusted 
mortality for users of each ß-blocker was calculated using Kaplan-Meier curves and 
compared using the log-rank test. To account for differences in follow-up and to 
control for differences among patient characteristics, a multivariate Cox propor-
tional hazards model was used to compare the all-cause mortality, cardiovascular 
mortality and HF readmission. We run also analysis by matching with a propensity 
score. Results: Of the 3,732 patients with HF, with a median follow-up of 3.1 years 
per patient, the crude annual incidence of death was 16.5% with metoprolol tartrate, 
15.8% with carvedilol, and 17.5% with bisoprolol. After controlling for several dif-
ferent covariates, we found that carvedilol (hazard ratio [HR] 0.95, 95% confidence 
interval [CI] 0.82-1.10) and bisoprolol (HR 1.06, 95% CI 0.95-1.18) were not superior to 
metoprolol tartrate in improving survival. Similar results were observed for cardio-
vascular mortality. But, HF readmission rate was significantly increased from 20 to 
26% with carvedilol and bisoprolol compare to metoprolol tartrate. ConClusions: 
Based on observational study, we suggest that there is no evidence of a class effect 
for β -blockers in older patients with HF on mortality, but the choice of β-blocker may 
have impact on the rate of HF readmission.
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objeCtives: Dyslipidaemia is an important and well recognised modifiable CV 
risk factor. This study was undertaken to determine the proportion of patients 
reaching and maintaining the low-density lipoprotein cholesterol (LDL-C) target in 
a large Canadian cohort and the prevalence of CV risk factors. Methods: We ret-
rospectively analysed data from an open cohort of patients initiating statin therapy 
between 2004 and 2012, using the Southwestern Ontario primary care practice data-
base. Inclusion criteria were: ≥ 2 years statin-free, diagnosis of dyslipidaemia, and ≥ 1 
statin prescription. Patients were stratified into three CV risk levels (low, intermedi-
ate, high); results are reported for the high-risk subgroup. CV risk factors and preva-
lence were estimated using 2012 data. Results: Of 41,733 patients who initiated 
statin therapy, 14,607 (35%) were at high CV risk. At baseline, the mean±SD age was 
54±7 years, 51% were male, and LDL-C was 3.07±0.41 mmol/L. In 2012, there were 
13,985 high-risk patients, with a mean±SD of 3±2 CV risk factors. The most frequent 
CV risk factors were: age (females > 55 years + males > 45 years: 91%, n= 12,727), 
obesity (body mass index > 27 kg/m2: 36%, n= 5,035), high-risk hypertension (31%, 
n= 4,395), history of CV disease (17%, n= 2,377), and diabetes (14%, n= 1,958). Among 
high-risk patients in 2012, 1,390 (10%) received no statins, of whom 1,266 (91%) had 
statin intolerance (SI) and only 17 (< 1%) received no lipid-lowering agent. Across 
2004–2012, patients took 6.7±2.2 months to reach the LDL-C target. After 1 year of 
statin treatment, 25% (n= 3,652) had not reached the target; this proportion remained 
stable over time. Among the 1,294 patients with SI, 84% were on target at SI diag-
nosis and only 49% were still on target 6 months post-SI. ConClusions: Despite 
widespread statin use, dyslipidaemia represents a significant burden for high-risk 
patients. Many patients do not achieve their LDL-C goals with statin therapy.
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objeCtives: Estimate annual utilization and cost of prostacyclins (PGI2) among 
patients with pulmonary arterial hypertension (PAH). Methods: Truven® 
Commercial and Medicare Databases were used to identify annual cohorts of adults 
with PAH (i.e., International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes [416.0 or 416.8] and ≥ 1 claims for PAH-
specific medications) between calendar-year (CY) 2010 and CY2014. Patients with 
≥ 1 claims for PGI2 were deemed PGI2 users. PGI2 use was categorized as parenteral 
vs. non-parenteral. PAH-related included costs of PAH-specific medications and all 
medical claims with a relevant diagnosis code. Results: A total of 12,306 patients 
met selection criteria for at least 1 CY of the study period. Annual prevalence of 
PGI2 use ranged from 20% to 22%. Among PGI2 users, treprostinil use increased 
from 50% in CY2010 to 71% in CY2014; corresponding decreases for epoprostenol 
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objeCtives: To assess, in a community setting, the clinical and economic outcomes 
of hypercholesterolemic patients with ACS and diabetes treated with statins over 
a one-year follow-up. Methods: Data for over 2.9 million subjects were extracted 
from 6 Local Health Units (ARNO Observatory, an administrative database contain-
ing data on hospitalizations, prescriptions and diagnostic/outpatient visits). The 
index period lasted from January 1 to December 31, 2011. Patients with ACS and dia-
betes were followed-up from the index hospitalization in 2011 for a period of 1 year. 
The rate of prescription, dosage, adherence to statin treatment and related health 
care costs were evaluated. Results: Of 2,989,512 subjects identified, 6,226 patients 
(0.2%) were hospitalized for ACS: 86.4% were aged over 60 years. Hospital death rate 
was 4.1%. Among ACS cases, 1,917 had diabetes (30.8%). At 1-year follow-up, 85.3% 
of patients with ACS and diabetes, were prescribed statin therapy with 84.9% being 
prescribed high intensity statins (Atorvastatin 40, 80 mg/dL, Rosuvastatin 20, 40 mg/
dL). Adherence to treatment (attributed to all patients who received the correct daily 
dosage during the one year follow-up period with a 20% tolerability – CORE Study 
2013) was higher among high intensity statins users compared to lower intensity 
statins users (67.1% vs 38.9%). Over the 1-year follow-up period, 69.3% of ACS dia-
betic patients were re-hospitalized, of which 55.6% were hospitalized for cardiovas-
cular events. The average yearly cost per patient supported by NHS was 16,897€ /year: 
14,199€ for hospitalizations; 1,691€ for drugs; 1,008€ for diagnostic and outpatient 
visits. ConClusions: Patients with ACS and diabetes have high direct healthcare 
costs, with re-hospitalization being the main cost driver. Adherence to statin treat-
ment was sub optimal. Local Health Authorities together with Cardiologists and 
GPs are working to bridge the gap between evidence-based recommendations and 
clinical practice in order to contain morbidity and health costs.
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objeCtives: Previously, we reported lipid modifying therapy (LMT) and low-density 
lipoprotein cholesterol (LDL-C) goal attainment among patients at high-risk for 
cardiovascular events. The objective of the current study was to describe clinical 
characteristics, lipid modifying therapy (LMT) treatment, and LDL-C attainment of 
a familial hypercholesterolemia (FH) cohort. Methods: For this cross-sectional 
study, the PHARMO Database Network was used. Patients aged ≥ 18 years with an 
LDL-C measurement in 2012 (index date) and ≥ 2 years of continuous enrollment 
in the pre-index period were considered. We identified FH patients by searching 
for a diagnosis of FH recorded by a general practitioner (GP) in the 2-year pre-index 
period or by application of the Dutch Lipid Clinic Network (DLCN) criteria (score 
≥ 6). Patients with a filled prescription for LMT within 45 days of index were con-
sidered to be taking the medication. LDL-C goal of ≤ 100mg/dL was considered at 
goal. Results: 1,132 patients were identified, with 92% having a recorded FH diag-
nosis by a GP. Mean (±SD) age was 57 (±14) years and 43% were male. Approximately 
33% had co-morbid diabetes, 42% had hypertension and the mean (±SD) LDL-C was 
138 (±58) mg/dL In total, 54% were currently treated with LMT; 13% high-intensity 
statin (atorvastatin 40/80mg, rosuvastatin 20/40mg, simvastatin 80mg); 39% mod-
erate-to low-intensity statin and 2% other non-statin LMT. LDL-C ≥ 100 mg/dl was 
observed in 77% of the patients and 27% had an LDL-C ≥ 160mg/dL. Among the 47% 
not currently treated with LMT, 89% had an LDL-C level ≥ 100 mg/dl and 74% had no 
evidence of any LMT in the pre-index period. ConClusions: These data suggest 
that FH patients in the Netherlands are undertreated by GPs and not at goal. This 
underscores the need for improving treatment rates with LMT and benefit of add-on 
treatment options in those not able to achieve goals on current LMTs.
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objeCtives: Describe demographics, clinical characteristics and treatment patterns 
(i.e., discontinuation, switching, or augmentation) of patients with pulmonary arterial 
hypertension (PAH) initiating prostacyclin (PGI2) therapy. Methods: Using Truven® 
Commercial and Medicare Databases (2010–2014), two non-mutually exclusive cohorts 
were constituted. The first consisted of initiators of parenteral PGI2 (P-PGI2); the sec-
ond, non-parenteral PGI2 (NP-PGI2). All patients were required to have evidence of 
PAH (i.e., ≥ 1 claims with a PAH diagnosis or ≥ 1 pharmacy claims for PAH-specific 
medications). Demographics and clinical characteristics were assessed during the 
three months prior to PGI2 initiation. Treatment patterns were assessed until switch/
discontinuation, or end of follow-up. Results: Of the 12,306 PAH patients identified 
during the study period, 1,569 (12.7%) were new initiators of PGI2 (755 [6.1%] for P-PGI2 
and 1,003 [8.2%] for NP-PGI2). Approximately 70% of each cohort was female. P-PGI2 
patients were nominally younger than NP-PGI2 patients (54.2 vs. 59.4 years), yet, had 
more comorbidities, hospitalizations, emergency room visits and mean (standard 
deviation [SD]) PAH-related medical costs than NP-PGI2 patients ($46,038 [$72,208] 
vs. $28,210 [$58,386]) during the three months before PGI2 initiation. P-PGI2 patients 
had less other PAH medication use than NP-PGI2 patients prior to PGI2 initiation (43% 
vs. 67%). Twenty-seven percent and 19% of P-PGI2 and NP-PGI2 patients, respectively, 
discontinued initial PGI2; mean (SD) weeks to discontinuation was 22 (35) and 20 (23). 
Only 7% of P-PGI2 and 11% of NP-PGI2 patients switched; mean (SD) weeks to switch 
was approximately 8 (12.5) in both groups. Augmentation with another PAH medica-
